PTPRC and carcinoma: CD45 has been revealed as a potent marker to differentiate hematopoietic cells from carcinoma cells in solid and fluid tumor tissue via flow cytometry (Acosta et al., 2016) and serves as a pan‐leukocyte marker (Ruffell et al., 2012), therefore ideal for detection of immune cells.